Aortic & peripheral vascular disease

Comparative Efficacy of Endovascular Revascularization Modalities for Symptomatic Infrapopliteal Peripheral Artery Disease: A Network Meta-Analysis

JACC Cardiovasc IntervPublished Systematic review and meta-analysis of randomised trials

Authors' conclusion

Compared with PTA, DCBs and DES demonstrated higher primary patency and lower binary restenosis, and DCBs reduced late lumen loss, percentage in-lesion diameter stenosis, and clinically driven target lesion revascularization.

Study context

Population
Patients with symptomatic infrapopliteal peripheral artery disease (PAD)
Participants
1,102 / 284 / 903 / 695
Comparison
Percutaneous transluminal angioplasty (PTA) vs bare-metal stents (BMS) vs DCB vs drug-eluting stents (DES)
  • PTAn = 1,102reference
  • BMSn = 284
  • Drug-coated balloons (DCBs)n = 903
  • DESn = 695
Methodological detailsrandom-effects
  • Random-effects

Pooled result

As reported in the abstract

Primary patency
Each group vs PTAOdds ratio (95% CI)P value
DCBs
2.66(1.52–4.64)
P = 0.001
DES
2.41(1.23–4.73)
P = 0.01

Further pooled results

OutcomeOR (95% CI)P value
Target lesion binary (>50%) restenosis — DCBs vs PTA0.40 (0.21–0.77)P = 0.006
Target lesion binary (>50%) restenosis — DES vs PTA0.28 (0.13–0.62)P = 0.002
Clinically driven target lesion revascularization0.47 (0.29–0.76)P = 0.002
Complete wound healing · decreased odds with BMS0.41 (0.20–0.85)P = 0.02
OutcomeMD (95% CI)P value
In-lesion diameter stenosis−10.04 (−19.20 to −0.88)P = 0.03
OutcomeMD (95% CI)P value
Late lumen loss · lowered with DCBs0.34 (−0.63 to −0.05)P = 0.02

Amputation, mortality

No significant differences across the 4 groups

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Comparative Efficacy of Endovascular Revascularization Modalities for Symptomatic Infrapopliteal Peripheral Artery Disease: A Network Meta-Analysis. JACC Cardiovasc Interv. Published 13 July 2026. doi:10.1016/j.jcin.2026.02.046

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.